AbCellera Biologics (ABCL) Operating Leases (2020 - 2026)

AbCellera Biologics has reported Operating Leases for 7 years, with the latest figure at $134.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 112.48% year-over-year to $134.3 million; the trailing twelve-month figure through Mar 2026 stood at $134.3 million (up 112.48% YoY), and the FY2025 full-year result was $137.4 million, up 126.2% from the prior year.
• Operating Leases for Q1 2026 stood at $134.3 million, down from $137.4 million in the prior quarter.
• The five-year high for Operating Leases was $137.4 million in Q4 2025, with the low at $32.8 million in Q2 2022.
• Historically, Operating Leases has averaged $82.4 million across 5 years, with a median of $75.2 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Leases jumped 162.58% — and 2024, when it slipped 21.5%.
• AbCellera Biologics' Operating Leases stood at $82.3 million in 2022, then decreased by 5.93% to $77.4 million in 2023, then fell by 21.5% to $60.7 million in 2024, then jumped by 126.2% to $137.4 million in 2025, then slipped by 2.25% to $134.3 million in 2026.
• The last three Operating Leases figures came in at $134.3 million (Q1 2026), $137.4 million (Q4 2025), and $137.1 million (Q3 2025), per Business Quant data.